IL275720B - Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders - Google Patents

Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders

Info

Publication number
IL275720B
IL275720B IL275720A IL27572020A IL275720B IL 275720 B IL275720 B IL 275720B IL 275720 A IL275720 A IL 275720A IL 27572020 A IL27572020 A IL 27572020A IL 275720 B IL275720 B IL 275720B
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
nos
Prior art date
Application number
IL275720A
Other languages
English (en)
Hebrew (he)
Other versions
IL275720A (en
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of IL275720A publication Critical patent/IL275720A/en
Publication of IL275720B publication Critical patent/IL275720B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL275720A 2013-10-21 2014-10-21 Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders IL275720B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361893814P 2013-10-21 2013-10-21
US201461979384P 2014-04-14 2014-04-14
US201462012805P 2014-06-16 2014-06-16
PCT/US2014/061592 WO2015061330A1 (en) 2013-10-21 2014-10-21 Use of semaphorin-4d binding molecules for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
IL275720A IL275720A (en) 2020-08-31
IL275720B true IL275720B (en) 2022-09-01

Family

ID=52826380

Family Applications (3)

Application Number Title Priority Date Filing Date
IL275720A IL275720B (en) 2013-10-21 2014-10-21 Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders
IL295045A IL295045B2 (en) 2013-10-21 2014-10-21 Use of molecules that bind semphorin-D4 to treat neurodegenerative disorders
IL245089A IL245089B (en) 2013-10-21 2016-04-13 Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL295045A IL295045B2 (en) 2013-10-21 2014-10-21 Use of molecules that bind semphorin-D4 to treat neurodegenerative disorders
IL245089A IL245089B (en) 2013-10-21 2016-04-13 Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders

Country Status (19)

Country Link
US (4) US9598495B2 (2)
EP (3) EP3639853B1 (2)
JP (2) JP6461944B2 (2)
KR (4) KR102308493B1 (2)
CN (2) CN106029093B (2)
AU (3) AU2014340210B2 (2)
BR (1) BR112016009047B1 (2)
CA (2) CA2927841C (2)
DK (1) DK3060252T3 (2)
EA (1) EA033072B1 (2)
ES (2) ES3063301T3 (2)
IL (3) IL275720B (2)
MX (2) MX374708B (2)
NZ (1) NZ630892A (2)
PL (1) PL3060252T3 (2)
PT (1) PT3060252T (2)
SG (2) SG10201707786QA (2)
WO (1) WO2015061330A1 (2)
ZA (1) ZA201602686B (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
AU2012322721B2 (en) 2011-10-11 2016-05-05 Vaccinex, Inc. Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US10626163B2 (en) * 2013-01-25 2020-04-21 Brandeis University Methods of modulating GABAergic inhibitory synapse formation and function
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
JP7084689B2 (ja) * 2016-12-08 2022-06-15 公益財団法人東京都医学総合研究所 脳組織の異常を伴う非ヒト動物の作製方法およびその利用
EP3585435A4 (en) * 2017-02-22 2020-12-16 Vaccinex, Inc. EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISEASES
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
CA3061963A1 (en) 2017-05-05 2018-11-08 Vaccinex, Inc. Human anti-semaphorin 4d antibody
CN109410218B (zh) * 2018-10-08 2020-08-11 百度在线网络技术（北京）有限公司 用于生成车辆损伤信息的方法和装置
EP3693380A1 (en) * 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
CN117597360A (zh) 2020-06-25 2024-02-23 瓦西尼斯公司 脑信号蛋白-4d结合分子在rett综合征治疗中的应用
JPWO2022137964A1 (2) * 2020-12-23 2022-06-30
JP2024535403A (ja) * 2021-09-27 2024-09-30 バクシネックス インコーポレーティッド 神経変性障害を処置するための抗セマフォリン４ｄ結合分子の使用に関する予測アウトカムプロファイリング
US20230101618A1 (en) * 2021-09-27 2023-03-30 Vaccinex, Inc. Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders
US20230331863A1 (en) 2022-02-13 2023-10-19 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
AU2024243083A1 (en) * 2023-04-03 2025-11-20 Sialbio Co., Ltd. Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient
CN117924494B (zh) * 2024-01-23 2025-02-25 首都医科大学附属北京积水潭医院 特异性结合sema4d的抗原结合蛋白及其应用
WO2026030311A1 (en) * 2024-07-29 2026-02-05 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules to treat cognitive impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055922A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CA2286477A1 (en) 1997-04-11 1998-10-22 Dendreon Corporation Composition and method for inducing an immune response against tumour-related antigens
EP0892047A3 (de) 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
ATE407206T1 (de) 1998-11-10 2008-09-15 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US7468277B2 (en) 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
US7919246B2 (en) 2005-04-07 2011-04-05 Novartis Vaccines And Diagnostics, Inc. SEMA4D in cancer diagnosis, detection and treatment
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
AR070134A1 (es) 2008-01-10 2010-03-17 Genentech Inc Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
NZ605260A (en) 2010-06-14 2013-12-20 Joseph King Allan Anti-vegf antibodies and uses thereof
MX343640B (es) 2011-05-13 2016-11-15 Nat Univ Corp Tokyo Medical & Dental Univ Promotor de osteogenesis.
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10577427B2 (en) 2016-04-22 2020-03-03 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
BR112019001944A2 (pt) 2016-08-02 2019-05-07 Vaccinex, Inc. métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia
EP3585435A4 (en) 2017-02-22 2020-12-16 Vaccinex, Inc. EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISEASES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055922A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASTERMAN, DONNA., TREATMENT OF THE NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE, 1 November 2013 (2013-11-01) *
PALMER, ALAN M., THE ROLE OF THE BLOOD BRAIN BARRIER IN NEURODEGENERATIVE DISORDERS AND THEIR TREATMENT., 1 January 2011 (2011-01-01) *
SRIKANTH, S.; NAGARAJA, A. V.; RATNAVALLI, E., NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA-FREQUENCY, RELATIONSHIP TO DEMENTIA SEVERITY AND COMPARISON IN ALZHEIMER'S DISEASE, VASCULAR DEMENTIA AND FRONTOTEMPORAL DEMENTIA, 15 September 2005 (2005-09-15) *

Also Published As

Publication number Publication date
US20190322757A1 (en) 2019-10-24
CA3193983A1 (en) 2015-04-30
ES2773961T3 (es) 2020-07-15
AU2021202095A1 (en) 2021-05-06
MX2016005050A (es) 2016-08-17
KR20160065981A (ko) 2016-06-09
MX2020009260A (es) 2020-10-01
KR20210118246A (ko) 2021-09-29
EP3060252A1 (en) 2016-08-31
CN106029093A (zh) 2016-10-12
EP4717270A2 (en) 2026-04-01
IL245089B (en) 2020-10-29
PT3060252T (pt) 2020-03-04
BR112016009047B1 (pt) 2024-02-06
JP6461944B2 (ja) 2019-01-30
CA2927841A1 (en) 2015-04-30
AU2014340210A1 (en) 2016-05-05
US9249227B2 (en) 2016-02-02
ZA201602686B (en) 2020-11-25
EP3060252A4 (en) 2017-06-07
EP3639853C0 (en) 2026-01-21
CN106029093B (zh) 2023-03-28
ES3063301T3 (en) 2026-04-16
AU2021202095B2 (en) 2023-11-02
AU2021202095B9 (en) 2023-11-09
EP3060252B1 (en) 2019-12-11
KR102602502B1 (ko) 2023-11-14
EA033072B1 (ru) 2019-08-30
IL275720A (en) 2020-08-31
WO2015061330A1 (en) 2015-04-30
CN116966293A (zh) 2023-10-31
US9598495B2 (en) 2017-03-21
PL3060252T3 (pl) 2020-05-18
SG11201603167YA (en) 2016-05-30
AU2014340210B2 (en) 2019-08-08
EP3639853B1 (en) 2026-01-21
IL295045B2 (en) 2024-04-01
JP2019059786A (ja) 2019-04-18
AU2019257379B2 (en) 2021-04-01
EP3639853A1 (en) 2020-04-22
JP6875363B2 (ja) 2021-05-26
AU2019257379A1 (en) 2019-11-14
KR20230159633A (ko) 2023-11-21
BR112016009047A2 (pt) 2017-09-19
NZ630892A (en) 2016-03-31
KR20220110853A (ko) 2022-08-09
IL295045A (en) 2022-09-01
JP2017502920A (ja) 2017-01-26
DK3060252T3 (da) 2020-03-16
US20150110800A1 (en) 2015-04-23
US10385136B2 (en) 2019-08-20
US20170198053A1 (en) 2017-07-13
IL245089A0 (en) 2016-06-30
EA201690813A1 (ru) 2016-08-31
US20150353641A1 (en) 2015-12-10
MX374708B (es) 2025-03-06
SG10201707786QA (en) 2017-10-30
CA2927841C (en) 2023-05-23
US10800853B2 (en) 2020-10-13
IL295045B1 (en) 2023-12-01
KR102308493B1 (ko) 2021-10-07

Similar Documents

Publication Publication Date Title
IL275720B (en) Use of molecules that bind semphorin-d4 for the treatment of neurodegenerative disorders
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
FI3322722T3 (fi) Aineita, käyttötapoja ja menetelmiä synukleinopatian hoitoon
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
WO2020121195A8 (en) Trem2 antibodies and uses thereof
JP2015530971A5 (2)
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008019061A3 (en) Anti-il-6 monoclonal antibodies and uses thereof
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
JP2017502920A5 (2)
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
PH12013502068A1 (en) Monoclonal antibodies against the rgm a protein and uses thereof
JP2017518258A5 (2)
WO2011151076A3 (en) Monoclonal antibodies targeting amyloid beta oligomers
WO2020065330A3 (en) Chimeric antigen receptor
WO2009048537A3 (en) Humanized antibody
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
WO2012009442A3 (en) Anti-addl monoclonal antibody and uses thereof
NZ758300A (en) Human anti-semaphorin 4d antibody
MX2016004928A (es) Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.